S Zimm
Overview
Explore the profile of S Zimm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balis F, Holcenberg J, Poplack D, Ge J, Sather H, Murphy R, et al.
Blood
. 1998 Nov;
92(10):3569-77.
PMID: 9808549
We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameters with...
2.
Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies
Berg S, Balis F, Zimm S, Murphy R, Holcenberg J, Sato J, et al.
J Clin Oncol
. 1992 Jan;
10(1):143-8.
PMID: 1727916
Purpose: Because there is a compelling need to develop new agents for intrathecal use, we investigated the safety, efficacy, and CSF pharmacokinetics of diaziquone (AZQ) following intrathecal administration in patients...
3.
Adamson P, Zimm S, Ragab A, Balis F, Steinberg S, Kamen B, et al.
Cancer Chemother Pharmacol
. 1992 Jan;
30(2):155-7.
PMID: 1600597
A phase II pediatric trial of a continuous intravenous infusion of 6-mercaptopurine (6MP) in patients with refractory leukemia was performed. The dosing schedule, 50 mg m-2 h-1 for 48 h,...
4.
Kirmani S, Zimm S, Cleary S, Mowry J, Howell S
Cancer Chemother Pharmacol
. 1990 Jan;
25(6):454-8.
PMID: 2311175
Intraperitoneal administration of ara-C produces a peritoneal/plasma concentration ratio of 330-1,000: In principle, optimal tumor-cell kill should be obtained when high ara-C concentrations ar maintained in the environment of the...
5.
Howell S, Kirmani S, Lucas W, Zimm S, Goel R, Kim S, et al.
J Clin Oncol
. 1990 Jan;
8(1):137-45.
PMID: 2295904
We conducted a phase II trial of intraperitoneal (IP) cisplatin (DDP) and etoposide (VP-16) in stage III and IV newly diagnosed ovarian carcinoma patients with residual disease of any size....
6.
Adamson P, Zimm S, Ragab A, Steinberg S, Balis F, Kamen B, et al.
Cancer Chemother Pharmacol
. 1990 Jan;
26(5):343-4.
PMID: 2208575
A phase II pediatric trial of a continuous intravenous infusion of 6-mercaptopurine (6-MP) in patients with refractory solid tumors or lymphoma was performed. The dosing schedule of 50 mg/m2 per...
7.
Goel R, Cleary S, Horton C, Balis F, Zimm S, Kirmani S, et al.
J Clin Oncol
. 1989 Feb;
7(2):262-9.
PMID: 2915241
Dipyridamole increases the toxicity of methotrexate in a concentration-dependent manner. We hypothesized that concurrent intraperitoneal administration of both drugs would result in high peritoneal concentrations with much lower plasma concentrations,...
8.
Zimm S, Cleary S, Horton C, Howell S
J Clin Oncol
. 1988 Apr;
6(4):696-700.
PMID: 3357007
Thioguanine (TG) is an antimetabolite with established antileukemic activity. The most pharmacologically rational manner of TG administration is continuous infusion. Intraperitoneal (IP) delivery of TG provides the opportunity to definitively...
9.
Chan T, Coppoc G, Zimm S, Cleary S, Howell S
Cancer Res
. 1988 Jan;
48(1):215-8.
PMID: 3334996
The pharmacokinetics of i.p. administered dipyridamole was studied in six patients to explore the feasibility of using this drug as a modulator of antimetabolite activity in extravascular spaces. Infusions of...
10.